Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bisphosphonates

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    138 result(s) found for: Bisphosphonates. Displaying page 3 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2008-003967-37 Sponsor Protocol Number: CV-9103-001 Start Date*: 2008-12-08
    Sponsor Name:CureVac GmbH
    Full Title: Safety and efficacy trial of a RNActive®-derived prostate cancer vaccine in hormone refractory disease
    Medical condition: patients with hormone-refractory prostate cancer (HRPC) with rising PSA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002887-29 Sponsor Protocol Number: Uni-Koeln-1574 Start Date*: 2013-02-13
    Sponsor Name:University of Cologne
    Full Title: Translational therapy in patients with Osteogenesis imperfecta - a pilot trial on treatment with the RANKL-antibody Denosumab
    Medical condition: In this study we will evaluate the efficacy of Denosumab in children with Osteogenesis imperfecta. Subjects will be treated every 12 weeks over 36 weeks with Denosumab 1mg/kg body weight s.c.. Effi...
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005364-65 Sponsor Protocol Number: Start Date*: 2007-06-27
    Sponsor Name:AUO
    Full Title: Intermittent Treatment with Taxotere and Prednisone in patients with asymptomatic, hormone-refractory prostate cancer: A Multicenter Phase II Trial
    Medical condition: asymptomatic hormone-refractory prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002370-64 Sponsor Protocol Number: AUPSG 01/07 Start Date*: 2007-06-11
    Sponsor Name:Austrian Prostate Study Group (AUPSG)
    Full Title: Multi-center, randomized, double-blind phase II study of sorafenib or placebo with best supportive care after failure of deocetaxol in metastatic hormone-refractory prostate cancer
    Medical condition: metastatic hormone-refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006085-40 Sponsor Protocol Number: 2011-006085-40 Start Date*: 2012-12-17
    Sponsor Name:Cliniques Universitaires Saint Luc
    Full Title: A proof of concept study to evaluate the use of metabonomics and lipidomics in predicting toxicity and efficacy of anti-VEGF therapy in patients with metastatic clear cell renal cell carcinoma.
    Medical condition: Metastatic clear cell renal cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-006055-52 Sponsor Protocol Number: CRAD001JDE15T Start Date*: 2009-01-09
    Sponsor Name:Charité - University Hospital of Berlin
    Full Title: Everolimus (RAD001) in combination with intravenous carboplatin in taxane- and anthracycline-pretreated patients with progressive metastatic breast cancer
    Medical condition: Breast cancer is the most prevalent malignancy in women and metastatic breast cancer is a leading cause of mortality, accounting for more than 400,000 deaths annually worldwide. Even though anthrac...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004545-15 Sponsor Protocol Number: MLAM 2007/01 Start Date*: 2008-06-10
    Sponsor Name:University Medical Center Utrecht
    Full Title: The Split Dose Study: Split dose Rhenium-188-HEDP regimen in hormone refractory prostate cancer patients with bone metastases; a phase I toxicity study and phase II efficacy study.
    Medical condition: Hormone refractory prostate cancer with painful bone metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002678-11 Sponsor Protocol Number: ICO-13-001 Start Date*: 2018-06-07
    Sponsor Name:Institut Català d’Oncologia
    Full Title: An open label biomarker pilot study of the antitumoral acrivity of denosumab in the pre-operative setting of early breast cancer
    Medical condition: early breast cancer
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-005200-19 Sponsor Protocol Number: I-CONIC Start Date*: 2022-05-09
    Sponsor Name:Västra Götalandsregionen/Onkologiska kliniken
    Full Title: Use of Imatinib to convert triple negative breast cancer into ER-positive breast cancer - "I-CONIC"
    Medical condition: Early Triple Negative Breast Cancer planned for surgery.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002669-13 Sponsor Protocol Number: 87RI21_0052 Start Date*: 2022-11-25
    Sponsor Name:Limoges University Hospital
    Full Title: The PENTO protocol in Medication-related osteonecrosis of the jaw (MRONJ): a single-center phase IIa trial
    Medical condition: Medication-related osteonecrosis of the jaw (MRONJ)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004859 10084881 Medication-related osteonecrosis of jaw LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-001496-20 Sponsor Protocol Number: ISRCTN43372330 Start Date*: 2008-06-06
    Sponsor Name:University College London
    Full Title: Breakthrough Breast Cancer & Cancer Research UK Genetic Breast Cancer Trial: A randomised phase II pilot trial of carboplatin compared to docetaxel for patients with metastatic genetic breast can...
    Medical condition: Metastatic breast cancer in women with BRCA1 or BRCA 2 mutation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PT (Completed) SE (Ongoing) ES (Ongoing) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017649-67 Sponsor Protocol Number: nnisbjl2009 Start Date*: 2010-06-22
    Sponsor Name:The Central Remedial Clinic and The Children's University Hospital
    Full Title: Bone Health in Duchenne Muscular Dystrophy- a case controlled study of Risedronate use
    Medical condition: Bone Health in Duchenne Muscular Dystrophy- a randomised controlled study of Risedronate use
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002524-34 Sponsor Protocol Number: 011941 Start Date*: 2006-02-01
    Sponsor Name:BAYER Healthcare AG
    Full Title: An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients with Advanced Renal Cell Carcinoma
    Medical condition: Advanced Renal Cell Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) ES (Completed) BE (Completed) DK (Completed) PT (Prematurely Ended) IT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005647-14 Sponsor Protocol Number: 07/cmc/4088e Start Date*: 2009-03-16
    Sponsor Name:Cardiff University
    Full Title: Gamma Delta T Cells and their role in the acute phase reaction to intravenous bisphosphonates
    Medical condition: Patients with osteoporosis or Paget's disease of bone
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031282 Osteoporosis LLT
    9.1 10033362 Paget's disease LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014796-51 Sponsor Protocol Number: 120BC201 Start Date*: 2010-02-02
    Sponsor Name:Biogen Idec Ltd.
    Full Title: Phase 2a, open-label, randomized, noncomparative study of BIIB021 in combination with exemestane in women with hormone receptor-positive, advanced metatatic breast cancer who have progressed on a n...
    Medical condition: Advanced Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002094-23 Sponsor Protocol Number: EORTC 30021 Start Date*: 2004-12-20
    Sponsor Name:EORTC
    Full Title: Randomized phase II trial of Docetaxel (Taxotere) and Oblimersen vs Taxotere alone in patients with HRPC
    Medical condition: Patients with Hormone- Refractory Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    7.0 10001186 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed) DE (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-014729-18 Sponsor Protocol Number: 5442-012-00 Start Date*: 2009-11-30
    Sponsor Name:Merck & Co., Inc.
    Full Title: “Un Ensayo de Fase IIb, Aleatorizado, Doble Ciego, Controlado con Placebo y Comparador Activo, de Determinación del Rango de Dosis para Evaluar los Efectos de MK-5442 en la Densidad Mineral Ósea ...
    Medical condition: Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    9 10031285 Osteoporosis postmenopausal LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) GB (Completed) CZ (Completed) DK (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-003183-19 Sponsor Protocol Number: CA180-261 Start Date*: 2009-02-16
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Randomized, Double-Blind, Multi-Center Phase 2 Trial of Exemestane (Aromasin®) plus Dasatinib versus Exemestane plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer after Disease Pro...
    Medical condition: Advanced Estrogen Receptor-Positive Breast Cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IE (Completed) CZ (Completed) IT (Completed) SE (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005665-12 Sponsor Protocol Number: MDV3100-14(C3431005) Start Date*: 2013-09-06
    Sponsor Name:Medivation, Inc., a wholly owned subsidiary of Pfizer Inc.
    Full Title: A Multinational, Phase 3, Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer
    Medical condition: Patients With Nonmetastatic Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) IT (Completed) AT (Completed) BE (Completed) GB (GB - no longer in EU/EEA) SK (Completed) FI (Completed) NL (Completed) ES (Completed) GR (Completed) FR (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005529-74 Sponsor Protocol Number: ML19982 Start Date*: 2006-03-16
    Sponsor Name:Roche (Hungary) Ltd.
    Full Title: A randomised, open-label, multi-national, multi-center study to investigate the impact of bone-marker feedback (at 3 months) on adherence to once monthly ibandronate treatment of patients with post...
    Medical condition: osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10031282 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SI (Completed) SK (Completed) LV (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Aug 02 09:34:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA